The trial results are due soon. It is common knowledge, from the...

The trial results are due soon. It is common knowledge, from the preliminary results that we can expect a significant result for children using the Mente autism device. The stock can only re-rate at that time. They will have significant data validating their device and a $17M mc will no longer be valid. $40-50M mc will be more appropriate as they already have distribution channels in place. At $50M mc the sp will be about 60 cents. If this news hits the media, which would be likely, then they can expect strong sales in the months after the trial results are released. They may receive US FDA approval as early as Q3 2018. This is also likely as the pathway for medical devices is much, much easier than it is for drugs. If this all falls into place then a MC of $150M is very reasonable with sp of around $2. GLTAH. I think this will be one of the best stocks for 2018